Back to Authors

Andò, Giuseppe

0000-0001-5552-6382

Mayo Clinic

Department of Clinical and Experimental Medicine, University of Messina and Azienda Ospedaliera Universitaria Policlinico "Gaetano Martino," Italy (G.A.).

Citations 2

Intensive Versus Standard Systolic Blood Pressure Targets Following Successful Endovascular Thrombectomy for Acute Ischemic Stroke: A Systematic Review With Frequentist and Bayesian Meta-Analysis
Ibrahim, A, Islam, M Rafiqul , Khalil, Ibrahim , Al‐Shammari, Ali Saad , Mourad, Sohaila , Balbaa, Elsayed, Elbenawi, Hossam , Sattar, Yasar , Katsanos, Aristeidis H. , Andò, Giuseppe , Ibrahim, Ahmed , Islam, M Rafiqul , Khalil, Ibrahim , Al-Shammari, Ali Saad , Balbaa, Elsayed , Sattar, Yasar , Katsanos, Aristeidis H , Andò, Giuseppe , Manasrah, AlMothana

Stroke: Vascular and Interventional Neurology | April 14, 2026 | Volume: 6 | Issue: 3 | Pages: No page available

10.1161/svin.125.002200 Get It

BACKGROUND: Blood pressure management following successful reperfusion with endovascular thrombectomy for acute ischemic stroke due to large vessel occlusion remains debated. This meta-analysis aimed to determine whether intensive systolic blood pressure (SBP) management improves clinical outcomes compared with a standard approach after endovascular thrombectomy. METHODS: We systematically searched PubMed, Scopus, Embase, and Web of Science through October 2025 for relevant randomized controlled trials comparing intensive (SBP target <140 mm Hg) versus standard (SBP target <180 mm Hg) management. The primary efficacy and safety outcomes were functional independence (modified Rankin Scale score, 0–2) and any intracranial hemorrhage, respectively. We performed frequentist and Bayesian random-effects meta-analyses, supplemented by trial sequential analysis. RESULTS: Six randomized controlled trials comprising 1972 patients were included. In frequentist analysis, intensive SBP management was associated with a significantly reduced likelihood of achieving functional independence (risk ratio, 0.83 [95% CI, 0.73–0.93]). Bayesian analysis confirmed this harmful effect (posterior median risk ratio, 0.83 [95% credible interval, 0.7–1.02]), with a posterior probability of benefit of only 3.2%. Furthermore, ordinal shift analysis indicated that intensive SBP management was associated with a significant shift toward worse functional outcomes across the full modified Rankin Scale score distribution (common odds ratio, 1.26 [95% CI, 1.10–1.44]), a finding supported by a low posterior probability of benefit of 2.1%. No significant differences were observed in the risk of any intracranial hemorrhage (risk ratio, 1.05 [95% CI, 0.96–1.16]). The corresponding Bayesian analysis yielded a posterior risk ratio estimate of 1.05 (95% credible interval, 0.90–1.21) for any intracranial hemorrhage, with a posterior probability of benefit of 23%. Trial sequential analysis indicated that the cumulative evidence reached the boundary for harm and futility for the primary efficacy and safety outcomes, respectively. CONCLUSIONS: In patients with acute ischemic stroke following successful endovascular thrombectomy, intensive SBP management was associated with worse functional outcomes and provided no clear safety benefit. These findings support a standard, guideline-based SBP management strategy over an intensive approach.
Efficacy and safety of clopidogrel versus aspirin monotherapy for secondary prevention after percutaneous coronary intervention: a GRADE-assessed meta-analysis with trial sequential analysis
Ibrahim, Ahmed, SammanTahhan, Imad, Af, Amer, Elbenawi, Hossam , Andò, Giuseppe, Tahhan, Imad Samman , Andò, Giuseppe , Katamesh, Basant E. , Andò, Giuseppe , Tahhan, Imad , Ibrahim, Ahmed , Almansouri, Naiela E , Sabouret, Pierre François

Journal of Cardiovascular Medicine | February 16, 2026 | Volume: 27 | Issue: 2 | Pages: 109-122

10.2459/jcm.0000000000001830 Get It

Background The optimal long-term antiplatelet monotherapy after percutaneous coronary intervention (PCI) with drug-eluting stents (DES) remains uncertain, with limited data comparing aspirin and clopidogrel monotherapy. This meta-analysis aims to compare the safety and efficacy of clopidogrel versus aspirin in patients who have completed a standard duration (≥6 months) of event-free dual antiplatelet therapy (DAPT) following PCI with DES. Methods A comprehensive literature search was conducted across major electronic databases through May 2025 to identify relevant studies that compared clopidogrel monotherapy with aspirin monotherapy in adults who had undergone PCI with DES implantation. The primary outcome was major adverse cardiac and cerebrovascular events (MACCE). Pooled estimates of relative risks (RRs) and adjusted hazard ratios (HRs) were calculated using a random-effects model. Results Five studies [two randomized controlled trials, three observational studies; n = 16, 289 patients] were included. Clopidogrel monotherapy was associated with a significant 31% reduction in MACCE compared with aspirin monotherapy [RR: 0.69; 95% confidence interval (CI) 0.60–0.79; P < 0.0001]. A pooled analysis of HRs demonstrated a similar benefit (HR: 0.67; 95% CI 0.58–0.77). Incidences of major bleeding and all-cause death were comparable between the two groups (RR: 0.93; 95% CI 0.57–1.51 and RR: 0.96; 95% CI 0.74–1.25, respectively). Notably, the analysis of HRs demonstrated that clopidogrel significantly reduced the risk of stroke (HR: 0.60; 95% CI 0.45–0.82; P = 0.001) and myocardial infarction (MI) (HR: 0.65; 95% CI 0.49–0.88; P = 0.005). Conclusion Clopidogrel monotherapy is more effective than aspirin for long-term prevention of MACCE, MI, and stroke, without increasing the major bleeding risk. Prospero ID CRD420251070685